Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer have?
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer has 486 citations in the OpenAlex counts ScholarIQ stores.
When was Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer published?
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer has 2023 year in the ScholarIQ index.
What is the open-access status of Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer?
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer has hybrid oa status in the ScholarIQ index.
What is the DOI of Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer?
The DOI for Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer is on the source record.
What is the PMID of Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer?
The PMID for Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer is on the source record.
What is the OpenAlex record for Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer?
The OpenAlex for Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer is on the source record.